Design efficiency in dose finding studies

DOI10.1016/S0167-9473(02)00323-7zbMATH Open1429.62583OpenAlexW2002952151MaRDI QIDQ956828FDOQ956828

Authors: Xavier Paoletti, John O'Quigley, Jean Maccario 

Publication date: 26 November 2008

Published in: Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/s0167-9473(02)00323-7

Recommendations

• Optimal designs for dose-finding studies
• Optimal designs for dose finding studies with an active control
• Dose Finding – A Challenge in Statistics
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint

zbMATH Keywords

clinical trialsefficiencyoptimalitydose findingphase I designs

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Cites Work

• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Title not available (Why is that?)
• Miscellanea. A stopping rule for the continual reassessment method
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• Non-parametric optimal design in dose finding studies
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• A Curve‐Free Method for Phase I Clinical Trials

Cited In (16)

• Robustness of Design in Dose–Response Studies
• Biometric practicesimple benchmark for complex dose finding studies
• Non-parametric optimal design in dose finding studies
• Coherence principles in dose-finding studies
• A modified Huber loss function for continual reassessment methods in clinical trials
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
• Cumulative cohort design for dose-finding
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
• Up-and-down designs for dose-finding
• Adaptive Bayesian compound designs for dose finding studies
• Adaptive clinical trial designs for phase I cancer studies
• Efficiency of bridging between related dose finding studies
• Target toxicity design for phase I dose-finding
• Prediction Approaches to Sequentially Searching for an Optimal Dose
• Continual reassessment and related dose-finding designs

This page was built for publication: Design efficiency in dose finding studies

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q956828)